^
    Galleri is a a multi-cancer, laboratory-developed test (LDT) for early cancer detection from blood. It is intended to be complementary to, and not a replacement of, U.S. guideline-recommended cancer screening. Galleri is a trademark of GRAIL, LLC.
    Cancer:
    Adrenal Cortex Carcinoma, Ampulla of Vater Carcinoma, Anal Carcinoma, Appendix Cancer, Bladder Cancer, Breast Cancer, Cervical Cancer, Colon Cancer, Esophageal Cancer, Fallopian Tube Cancer, Gallbladder Cancer, Gastroesophageal Junction Adenocarcinoma, Gastrointestinal Stromal Tumor, Hodgkin Lymphoma, Kidney Cancer, Leukemia, Liver Cancer, Lung Cancer, Malignant Pleural Mesothelioma, Melanoma, Merkel Cell Carcinoma, Neuroendocrine Tumor, Non-Hodgkin’s Lymphoma, Oral Cancer, Ovarian Cancer, Pancreatic Cancer, Penile Cancer, Peritoneal Cancer, Prostate Cancer, Rectal Cancer, Renal Cell Carcinoma, Small Intestinal Carcinoma, Soft Tissue Sarcoma, Testicular Cancer, Urethral Cancer, Uterine Cancer, Vaginal Cancer, Vulvar Cancer
    Method:
    Next-Generation Sequencing (NGS)
    Confirmatory trial(s)
    PATHFINDER
    ,
    NCT04241796
    |
    ASCO 2021